Compounds > sb 297006
Page last updated: 2024-12-11

sb 297006

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SB 297006: a CC chemokine receptor-3 antagonist that inhibits binding of eotaxin and monocyte chemotactic protein-4 to eosinophils; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9840971
CHEMBL ID284954
SCHEMBL ID3936094
MeSH IDM0375495

Synonyms (27)

Synonym
sb297006
ethyl (2s)-2-benzamido-3-(4-nitrophenyl)propanoate
CHEMBL284954 ,
(s)-2-benzoylamino-3-(4-nitro-phenyl)-propionic acid ethyl ester
bdbm50100041
SCHEMBL3936094
(s)-ethyl-2-benzoylamino-3-(4-nitrophenyl)propionate
BEZXGSZPWXRHIN-INIZCTEOSA-N
58816-69-6
sb 297006
n-benzoyl-4-nitroaniline ethyl ester
B6053
AKOS024458038
sb-297006
sb 297006, >=98% (hplc)
(s)-ethyl 2-benzamido-3-(4-nitrophenyl)propanoate
EX-A2738
ethyl (s)-2-benzamido-3-(4-nitrophenyl)propanoate
n-benzoyl-4-nitro-l-phenylalanine, ethyl ester
CS-0027745
HY-103361
(s)-ethyl2-benzamido-3-(4-nitrophenyl)propanoate
mfcd19690954
C75752
AS-56057
AC-36264
AKOS040758614
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 3Homo sapiens (human)IC50 (µMol)0.04900.00060.60419.0000AID42347
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
positive regulation of endothelial cell proliferationC-C chemokine receptor type 3Homo sapiens (human)
chemotaxisC-C chemokine receptor type 3Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 3Homo sapiens (human)
cell adhesionC-C chemokine receptor type 3Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayC-C chemokine receptor type 3Homo sapiens (human)
positive regulation of angiogenesisC-C chemokine receptor type 3Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 3Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 3Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 3Homo sapiens (human)
immune responseC-C chemokine receptor type 3Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
chemokine receptor activityC-C chemokine receptor type 3Homo sapiens (human)
protein bindingC-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneC-C chemokine receptor type 3Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 3Homo sapiens (human)
cytoplasmC-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID42347Inhibitory activity against human eosinophil C-C chemokine receptor type 3 using [125I]- human eotaxin as the radioligand2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.9640amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		2.0810xanthene
benzoyltyrosine ethyl ester
ethyl N-benzoyl-L-tyrosinate : An L-tyrosine derivative that is the ethyl ester of N-benzoyltyrosine.		210benzamides;
ethyl ester;
L-tyrosine derivative;
phenols		chromogenic compound
5-oxo-6,8,11,14-eicosatetraenoic acid
5-oxo-6,8,11,14-eicosatetraenoic acid: RN given is for cpd without isomeric designation; an arachidonate metabolite which stimulates neutrophils to mobilize Ca and promotes PMN degranulation responses		2.0810
ucb 35625
UCB 35625: J-113863 is the (trans)-isomer; structure in first source		2.0810
sb 328437
SB 328437: a CC chemokine receptor-3 antagonist that inhibits binding of eotaxin and monocyte chemotactic protein-4 to eosinophils; structure in first source		2.9440
ConditionIndicatedRelationship StrengthStudiesTrials
Asthma, Bronchial
[description not available]		02.4420
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		02.4420
Anoxia-Ischemia, Brain
[description not available]		02.1510
Acute Brain Injuries
[description not available]		02.1510
Brain Vascular Disorders
[description not available]		02.1510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1510
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		02.1510
Cerebrovascular Disorders
A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.		02.1510
Hypoxia-Ischemia, Brain
A disorder characterized by a reduction of oxygen in the blood combined with reduced blood flow (ISCHEMIA) to the brain from a localized obstruction of a cerebral artery or from systemic hypoperfusion. Prolonged hypoxia-ischemia is associated with ISCHEMIC ATTACK, TRANSIENT; BRAIN INFARCTION; BRAIN EDEMA; COMA; and other conditions.		02.1510
Innate Inflammatory Response
[description not available]		02.0310
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0310
Bronchial Hyperreactivity
Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.		02.0310